Guggenheim Initiates Coverage On MapLight Therapeutics with Neutral Rating
Guggenheim analyst Delma Caiati initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Neutral rating.
Stocks · News reference
HC Wainwright & Co. Maintains Buy on MapLight Therapeutics, Lowers Price Target to $26
HC Wainwright & Co. analyst Raghuram Selvaraju maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and lowers the price target from $45 to $26.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
MapLight Therapeutics Files Prospectus Related To The Resale Of Up To 13,181,055 Common Shares By Selling Stockholders
-SEC Filing
Needham Maintains Buy on MapLight Therapeutics, Lowers Price Target to $43
8-K filing — MapLight Therapeutics, Inc. (MPLT)
Filed: 2026-08-13 AccNo: 0001193125-26-349490 Size: 4 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.02: Results of Operations and Financial Condition Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits